Shield Therapeutics is a high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
As a unified team we are constantly driven by and committed to our goals, seeking to deliver them with transparency and respect. Being consistent to this vision, while enjoying the journey, has brought us to where we are today.
Stay up to date with the exciting new developments as we continue to grow.
STX_PK Paediatric Study_Final_14June18
For further details please see the press release below: STX_RNS Board Change
STX_RNS AGM NOTICE
Shield Therapeutics plc (LSE:STX) today announces its preliminary Group results for the year ended 31 December 2017. For full details view the press release here.
For further details please see the press release attached. STX_Confirms NED appointment
Shield Therapeutics announces results from it's Pre-Submission meeting with the FDA and confirms plans to submit a New Drug Application for Feraccru. This press release…
Shield Therapeutics announce that it has received EU Commission approval for the broadening of the indication for Feraccru® (Ferric Maltol) to the treatment of Iron…
Shield Therapeutics announces an update following detailed analyses of the data from the double-blind period of the AEGIS-CKD study, which it has presented to the…
Shield Therapeutics announced to the market today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted…
